López NM, Rodríguez WFL

Language: Spanish
References: 20
Page: 166-173
PDF size: 79.19 Kb.

ABSTRACT

Emergency departments should be prepared for the attention of patients who have any disease that represents life threatening or viability of any organ or function, such as the case of oncologic emergencies. The clinical assessment by the physician with therapeutic sources nowadays let us recognize more frequently these complications that could be developed in a large period of time among months, or even been installed in hours, so that treatment must be started immediately.

REFERENCES

1. Kwok Y, DeYoung C, Garofalo M et al. Radiation oncology emergencies. Hematol Oncol Clin N 2006; 6: 505-522.

2. Sverha J, Borenstein M. Emergency complications of malignancy. En: Meldon SW, John O, Woolard R. Geriatric Emergency Medicine. 1ST Ed. U.S.A. Mc Graw-Hill. 2003: 506-516.

3. Higdon M, Higdon J. Treatment of oncologic emergencies. Am Fam Physician 2006; 74: 1873-1880.

4. Tintinalli J, Gabor D, Stwphan J. Emergency complications of malignancy. Tintinalli´s emergency medicine: a comprehensive study guide. 5TH edition. U.S.A. Mc Graw-Hill Inc. 2000: 1408-1414.

5. Borenstein M, Silverstein S. Oncologic emergencies. In: Peter Rosen, M.D, Roger M. Barkin, M.D,,M.P.H. Emergency Medicine. 3° Ed. U.S.A. Mosby Year Book Inc. 1992: 1711-1727.

6. Robinson B. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603.

7. Wilson L, Detterbeck F, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356: 1862-1869.

8. Roodman. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19: 3562-3571.

9. Stewart A. Hypercalcemia associated with cancer. N Engl J Med 2005; 352(4): 373-379.

10. Cheer S. Zolendronic acid. Drugs 2001; 61: 799-805.

11. Gertz M, Fonseca R, Rajkumar. Waldenström´s macroglobulinemia. Oncologist 2000; 5: 63-67.

12. Thiebaut A. Thomas X, Belhabri A, Anglaret B, Archimbaud E. Impact of preinduction therapy leukapheresis on treatment outcome in adult myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000; 79: 501-506.

13. Gordon HW. Enfermedades de la corteza suprarrenal. En: Kasper DL, Braunwald E, Anthony S. Fauci, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ, Eds. Harrison-Tratado de Medicina Interna. 16a edición. México. Mc Graw-Hill. 2006. Cap 321.

14. Davidson M, Thakkar S, Hix J. Pathophysiology, clinical consequences and treatment of tumor lysis syndrome. Am J Med 2004; 116: 546-554.

15. Hughes WT et al. 2002 Guidelines for the Use of antimicrobial agents in neutropenic patients with cancer. CID 2002: 34:36.

16. Smith G, Toonen T. Primary care of the patient with cancer. Am Fam Physician 2007; 75(8): 1207-1214.

17. Lyman G. Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone 2006; 8(5): S12-S18.

18. Kemp SF, Richard F. Lockey MD. Anaphylaxis: A Review of causes and mechanisms. J Allerg Clin Immunol. 2002; 110(3): 341-348.

19. Lieberman P. Anaphylaxis. Med Clin N Am 2006; 90:77-95.

20. Tirado L, Mohar A. Epidemiología de las neoplasias hemato-oncológicas. Rev Inst Nal Cancerol 2007; 2: 109-120.